Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IONIS PHARMACEUTICALS, INC.

(IONS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2021 06/18/2021 06/21/2021 06/22/2021 06/23/2021 Date
37.48(c) 37.79(c) 36.91(c) 37.69(c) 37.78(c) Last
741 471 2 251 416 1 206 547 1 093 799 968 915 Volume
+0.94% +0.83% -2.33% +2.11% +0.24% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 617 M - -
Net income 2021 -260 M - -
Net Debt 2021 460 M - -
P/E ratio 2021 -20,1x
Yield 2021 -
Sales 2022 670 M - -
Net income 2022 -253 M - -
Net Debt 2022 429 M - -
P/E ratio 2022 -21,3x
Yield 2022 -
Capitalization 5 326 M 5 326 M -
EV / Sales 2021 9,38x
EV / Sales 2022 8,59x
Nbr of Employees 757
Free-Float 95,0%
More Financials
Company
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of... 
Sector
Biotechnology & Medical Research
Calendar
06/22 | 12:00pmPresentation
More about the company
Ratings of Ionis Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about IONIS PHARMACEUTICALS, INC.
06/14IONIS PHARMACEUTICALS  : ' Chief Scientific Officer C. Frank Bennett, Ph.D., rec..
PR
06/11BIOGEN  : New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA..
AQ
06/10IONIS PHARMACEUTICALS  : ' antisense therapies in ATTR amyloidosis to be feature..
PR
06/10BIOGEN : Research Supports Development of Investigational Higher Dose of Spinraz..
DJ
06/04IONIS PHARMACEUTICALS  : announces changes to its board of directors at annual m..
PU
06/04IONIS PHARMACEUTICALS INC  : Change in Directors or Principal Officers, Submissi..
AQ
06/03IONIS PHARMACEUTICALS  : announces changes to its board of directors at annual m..
AQ
05/26IONIS PHARMACEUTICALS  : to present at upcoming investor conferences
PR
05/20LIPODYSTROPHY PIPELINE : Emerging Therapies and Key pharma players involved by D..
AQ
05/14IONIS PHARMACEUTICALS  : SVB Leerink Adjusts Ionis Pharmaceuticals' Price Target..
MT
05/07IONIS PHARMACEUTICALS  : UBS Lifts Ionis Pharmaceuticals to Neutral From Sell, P..
MT
05/06IONIS PHARMACEUTICALS  : Morgan Stanley Adjusts Price Target on Ionis Pharmaceut..
MT
05/06IONIS PHARMACEUTICALS  : reports first quarter 2021 financial results and recent..
AQ
05/06IONIS PHARMACEUTICALS  : to present at upcoming investor conferences
PR
05/05IONIS PHARMACEUTICALS  : to host 2021 virtual annual meeting of stockholders
PR
More news
News in other languages on IONIS PHARMACEUTICALS, INC.
06/22IRW-PRESS  : Antisense Therapeutics Limited: Antisense: Rückmeldung der EMA zum ..
06/01IRW-PRESS : Antisense Therapeutics Limited: Antisense Therapeutics: Rückmeldung ..
05/26IRW-PRESS : Antisense Therapeutics Limited: Antisense Therapeutics: Herstellung ..
03/24MORNING BRIEFING - Deutschland/Europa -2-
03/23MÄRKTE USA/Deutliche Verluste nach Powell-Aussagen
More news
Analyst Recommendations on IONIS PHARMACEUTICALS, INC.
More recommendations
Chart IONIS PHARMACEUTICALS, INC.
Duration : Period :
Ionis Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IONIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 37,78 $
Average target price 56,56 $
Spread / Average Target 49,7%
EPS Revisions
Managers and Directors
NameTitle
Brett P. Monia Chief Executive Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Executive VP-Finance
Joseph Loscalzo Chairman
C. Frank Bennett Chief Scientific Officer & Executive VP
Sanjay Bhanot Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
IONIS PHARMACEUTICALS, INC.-33.18%5 326
MODERNA, INC.102.97%88 882
LONZA GROUP AG14.06%52 367
IQVIA HOLDINGS INC.35.24%46 761
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-10.43%28 797